EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access

LSD1-targeted therapy—a multi-purpose key to unlock immunotherapy in small cell lung cancer

Martin Sattler, Ravi Salgia

Translational Lung Cancer Research · 2023-06 · 12 (6) · 1350-1354

DOI: 10.21037/tlcr-23-40 ↗

Kurz gefasst

Editorial in der Zeitschrift Translational Lung Cancer Research, 2023-06. Verfasst von Martin Sattler und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

LSD1Small cell lung cancer (SCLC)epigeneticsimmune checkpoint blockade

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.

Zitieren

APA

Sattler, M., & Salgia, R. (2023). LSD1-targeted therapy—a multi-purpose key to unlock immunotherapy in small cell lung cancer. Translational Lung Cancer Research, 12(6), 1350-1354. https://doi.org/10.21037/tlcr-23-40

Vancouver

Sattler M, Salgia R. LSD1-targeted therapy—a multi-purpose key to unlock immunotherapy in small cell lung cancer. Translational Lung Cancer Research. 2023;12(6):1350-1354. doi:10.21037/tlcr-23-40

BibTeX
@article{Sattler2023,
  author = {Sattler, Martin and Salgia, Ravi},
  title = {LSD1-targeted therapy—a multi-purpose key to unlock immunotherapy in small cell lung cancer},
  journal = {Translational Lung Cancer Research},
  year = {2023},
  volume = {12},
  number = {6},
  pages = {1350--1354},
  doi = {10.21037/tlcr-23-40}
}
Kostenlos starten →